Status:
COMPLETED
The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)
Lead Sponsor:
Taiho Pharmaceutical Co., Ltd.
Conditions:
Breast Cancer
Eligibility:
FEMALE
20-65 years
Phase:
PHASE3
Brief Summary
This controlled study is designed to evaluate the relapse-free survival of UFT + TAM compared with CMF + TAM. Patients are randomly assigned to receive either CMF + TAM or UFT + TAM within 6 weeks aft...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age 20 to 65
- Hematopoietic WBC ≥ 4,000/mm\^3 Platelet ≥ 100,000/mm\^3 Hemoglobin ≥ 11.0 g/dL
- Hepatic AST and ALT ≤ 40 U/L Total bilirubin ≤ 1.5 mg/dL
- Renal BUN ≤ 25 mg/dL Creatinine ≤ 1.5 mg/dL
Exclusion
Key Trial Info
Start Date :
July 1 1996
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2008
Estimated Enrollment :
680 Patients enrolled
Trial Details
Trial ID
NCT00152178
Start Date
July 1 1996
End Date
August 1 2008
Last Update
July 7 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Osaka Medical Center for Cancer and Cardiovascular Diseases
1-1-3, Nakamichi, Higashinari-ku, Osaka, Osaka, Japan